This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary CXCR4 Therapeutic Antibody Development
Many members of the GPCR family have been proven to be pharmacological targets for numerous drugs. CXCR4, a G protein-coupled receptor, is found to have enhanced expression in many tumors. To assist in discovering the therapeutic potential of the CXCR4 target in veterinary applications, BioVenic has established a platform for the development of veterinary CXCR4 therapeutic antibodies. We offer comprehensive services covering the entire spectrum of antibody development, from antibody preparation to purification and engineering.
Background of CXCR4
| Full Name | C-X-C motif chemokine receptor 4 |
|---|---|
| Aliases | CD184, D2S201E, FB22, HM89, HSY3RR, LAP-3, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R, WHIM, WHIMS, WHIMS1. |
| Target Profile | Chemokine receptors (CXCR) are integral transmembrane proteins involved in the homing of leukocytes. By interacting with their corresponding ligands, CXCRs facilitate key cellular activities such as directed migration. Widespread expression of CXCR4 is seen across numerous tissues and organs, including on the surface of cells derived from bone marrow, umbilical cord blood, mobilized peripheral blood, as well as several non-hematopoietic stem cells. Cancer cells equipped with CXCR4 tend to metastasize to areas with higher concentrations of CXCL12, like the lungs, bones, lymph nodes, and liver. |
MoA of CXCR4
The primary ligand of CXCR4 is CXCL12. Specific binding of CXCL12 to CXCR4 induces conformational changes in its extracellular domain, allowing the chemokine to tightly bind to the receptor pocket. This is followed by a second conformational change, activating the intracellular trimeric G protein. Subsequently, a series of downstream intracellular signaling pathways and effector molecules are activated, such as RAS-RAF-ERK1/2, MAPK, and PI3K-AKT-NF-κB pathways, thereby regulating biological behaviors like cell survival, proliferation, migration, and adhesion. In tumors, this interaction can promote the growth, migration, and metastasis of tumor cells.
Fig.1 Schematic diagram of CXCR4/CXCL12 signaling pathways.1
Application in Veterinary Therapeutics
Specific chemokine receptors expressed by various tumor cells, when binding to their homologous ligands, may promote tumor growth, invasion, and metastasis by inducing angiogenesis, protease secretion, and directed cell migration. The high expression and functionality of CXCR4 have been confirmed in canine osteosarcoma and feline mammary carcinoma. Beyond cancer, in immune diseases such as feline immunodeficiency virus infection, FIV infection depends on CXCR4, which acts as a receptor for FIV, facilitating the virus's entry into cells. Therefore, targeting CXCR4 will open new avenues for the development of therapeutic antibodies for a variety of canine and feline diseases.
Veterinary CXCR4 Therapeutic Antibody Development Services
As one of the universally expressed chemokine receptors on tumor cells, CXCR4 is associated with the development and metastasis of various cancers, holding significant potential in the field of animal cancer therapy. BioVenic offers veterinary CXCR4 therapeutic antibody development services. Utilizing different technologies such as hybridoma cells, single B cells, and phage display for the preparation of veterinary therapeutic antibodies, complemented with subsequent characterization and engineering services, we assist in developing high-quality veterinary CXCR4 therapeutic antibodies.
For more information about our veterinary CXCR4 therapeutic antibody development services, please click the following link.
Why Choose Us?
We have established a diverse platform for veterinary therapeutic antibody development, encompassing technologies such as hybridoma, single B cell, and phage display.
Comprehensive engineering services for veterinary therapeutic antibodies are provided to enhance the affinity of antibodies and extend their half-life.
We also offer species-specific antibody development services to reduce the likelihood of adverse reactions caused by heterologous components.
As a member of the chemokine family, CXCR4 mediates organ-specific metastasis of solid tumors in companion animals through its interaction with CXCL12. Beyond cancer, CXCR4 also plays a role in other immune-related diseases. Considering the therapeutic potential of antibodies targeting CXCR4, BioVenic provides veterinary CXCR4 therapeutic antibody development services. Relying on our diverse proprietary technology platforms, we assist in the preparation and engineering of antibodies. If you have a need to develop veterinary therapeutic antibodies targeting CXCR4, please do not hesitate to contact us now!
Reference
- Walenkamp, Annemiek ME, et al. "CXCR4 ligands: the next big hit?." Journal of Nuclear Medicine 58.Supplement 2 (2017): 77S-82S.